68Ga-XHER2 PET/CT imaging to see HER2 in solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study tests a new HER2-targeted radiotracer, 68Ga-XHER2, for PET/CT imaging across various solid tumors. Tumor uptake will be measured with SUVmax and compared to HER2 expression measured by immunohistochemistry on tissue samples. The goal is to determine whether 68Ga-XHER2 PET/CT can reliably indicate HER2 status without invasive biopsy. Enrollment includes adults with suspected, newly diagnosed, or previously treated solid tumors who will have both standard imaging and the new PET/CT performed.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* adult patients (aged 18 years or older)
* patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report)
* patients who had scheduled both standard-of-care imaging and 68Ga-XHER2 PET/CT scans
* patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee

Exclusion Criteria:

* patients with pregnancy
* the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent

Where it's running

• The First Affiliated Hospital of Xiamen University
  Xiamen, Fujian, China Recruiting

Study contacts

• Study coordinator: Liang Zhao, MD, PhD
• Email: wzhaoliang01@163.com
• Phone: 18818350620

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 68Ga-XMFH01 PET/FL imaging to guide prostate cancer surgery

  This study tests a new dual-modality imaging probe, 68Ga-XMFH01, to preoperatively detect prostate cancer and guide the surgeon with fluorescence during operations in adults with newly diagnosed prostate cancer.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07885423

• Trastuzumab plus serplulimab with chemotherapy for HER2-positive advanced biliary tract or urothelial cancer after prior therapy

  This study will test whether adding trastuzumab and serplulimab to chemotherapy helps people with HER2-positive unresectable or metastatic biliary tract cancer or urothelial carcinoma who have not responded to standard treatment.

  Recruiting Phase 2 China Medical University, China · Shenyang, Liaoning · NCT07506057

• DLL3-targeted PET/CT for detecting neuroendocrine carcinoma

  We are testing a DLL3-targeted PET/CT scan to see if it better finds tumors in adults with suspected or confirmed neuroendocrine carcinoma.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07458906

• Driving pressure adjustment for high-frequency jet ventilation during tumor ablation

  This study will test whether using a height-based driving pressure for high-frequency jet ventilation improves breathing stability during thermal ablation in adults with non-brain solid tumors.

  Recruiting at 5 sites Nantes University Hospital · Lyon and 6 other locations · NCT07408375

• Selective ERBB2 inhibitor CGT4255 for adults with ERBB2-altered advanced solid tumors

  This trial tests a targeted drug called CGT4255 in adults with advanced solid tumors that have ERBB2 (HER2) changes to see if it is safe and shows anti-tumor activity.

  Recruiting at 15 sites Phase 1 Cogent Biosciences, Inc. · Scottsdale, Arizona and 14 other locations · NCT07361562

• Tracking HER2 mutations and treatment patterns in advanced non-small cell lung cancer in Italy

  This project will see how people in Italy with advanced NSCLC and HER2 mutations are diagnosed and treated over a one-year follow-up period.

  Recruiting at 2 sites Gruppo Oncologico Italiano di Ricerca Clinica · Bari, BA and 21 other locations · NCT07356544

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.